Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis
Daniel S. Graciaa, Maia Kipiani, Matthew J. Magee, Lali Mikiashvili, Ketevan Barbakadze, Nino Bablishvili, Sara C. Auld, Wael A. Alghamdi, et al. (13 authors)
Antimicrobial Agents and Chemotherapy · 2022-08
Abstract
Although linezolid is effective for multidrug-resistant TB (MDR-TB) tuberculosis treatment, it is associated with cytopenias after 4 weeks of administration. Data on toxicities with long-term use of linezolid and drug pharmacodynamics in MDR-TB treatment are limited, and concerns about toxicity present barriers to wider implementation.
MeSH terms
- Linezolid
- Medicine
- Tuberculosis
- Multiple drug resistance
- Antibiotics
- Extensively drug-resistant tuberculosis
- Pharmacodynamics
- Pharmacology